Dermatology and Therapy最新文献

{"title":"Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.","authors":"Tiago Torres, Jensen Yeung, Vimal H Prajapati, Simone Ribero, Anna Balato, Angelo Valerio Marzano, Maria João Cruz, Maria João Paiva Lopes, Elizabeth Lazaridou, Jose-Manuel Carrascosa, José Miguel Alvarenga, Pedro Farinha, Bruno Duarte, Monica Munera-Campos, Siddhartha Sood, Brian D Rankin, Michela Ortoncelli, Stefano Caccavale, Silvia Mariel Ferrucci, Gilberto Pires Rosa, Athina Ioanna Daponte, Gianmarco Silvi, Ketty Peris, Niccolò Gori, Francesca Prignano, Antonio Kolios, Pedro Herranz, Stamatios Gregoriou, Natalia Rompoti, Spyridon Gkalpakiotis, Andrea Chiricozzi","doi":"10.1007/s13555-025-01453-8","DOIUrl":"10.1007/s13555-025-01453-8","url":null,"abstract":"<p><strong>Introduction: </strong>Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial. In this international, multicenter, retrospective, comparative study we aimed to evaluate the 52-week effectiveness, safety, and tolerability of dupilumab, tralokinumab, and upadacitinib in patients with AD aged ≥ 12 years.</p><p><strong>Methods: </strong>Effectiveness was assessed at weeks 16, 24, and 52 using Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (NRS) scores. Safety was measured via adverse events (AEs).</p><p><strong>Results: </strong>A total of 1286 treatment courses were included: 62.5% received dupilumab, 24.3% received upadacitinib, and 13.1% received tralokinumab. Upadacitinib demonstrated higher effectiveness than dupilumab and tralokinumab across all time points and most evaluated outcomes both on the overall population and the biologic-/JAKi-naïve population, including stringent treatment targets such as EASI 90 response and combined EASI 90 + itch NRS 0/1 response. While upadacitinib demonstrated superior effectiveness, it was associated with a higher incidence of AEs, both leading to and not leading to treatment discontinuation, including thromboembolic events, lipid abnormalities, and hematologic abnormalities. In contrast, conjunctivitis was the most frequently observed AE among patients receiving biologics.</p><p><strong>Conclusion: </strong>This study provides a comprehensive real-world comparison of dupilumab, tralokinumab, and upadacitinib in AD, highlighting upadacitinib's superior effectiveness in achieving stringent treatment targets, both in the short and long term, but also a higher incidence of AEs. However, the considerable heterogeneity of the study population, an inherent limitation of real-world studies, must be acknowledged when interpreting these findings.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2295-2305"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scalp Microbiome Dynamics Can Contribute to the Clinical Effect of a Novel Antiseborrheic Dermatitis Shampoo Containing Patented Antifungal Actives: A Randomized Controlled Study.","authors":"Martine Maître, Sophie Baradat, Mélanie Froliger, Virginie Turlier, Aimée Simcic-Mori, Eléonore Gravier, Camille Géniès, Christophe Lauze, Céline Huyghe, Anaïs Noustens, Sandrine Alvarez-Georges, Rasvan Marinescu, Pascal Reygagne, Sandrine Bessou-Touya, Valérie Mengeaud, Hélène Duplan","doi":"10.1007/s13555-025-01408-z","DOIUrl":"10.1007/s13555-025-01408-z","url":null,"abstract":"<p><strong>Introduction: </strong>Scalp seborrheic dermatitis (SD) can cause physical discomfort and social embarrassment in affected individuals. Mild-to-moderate scalp SD can be managed using topical products with antifungal, antiinflammatory, and keratolytic properties.</p><p><strong>Methods: </strong>A two-phase, randomized, controlled study was conducted to evaluate the clinical efficacy of a newly formulated anti-SD shampoo containing two patented antifungal actives and to investigate the associated changes in the scalp microbiota. The intervention involved a 2-week intensive phase for the 42 subjects included in the study, consisting of the application of the anti-SD shampoo three times a week; a randomized [1:1], controlled, parallel-group 8-week maintenance phase consisting of the test group applying the study shampoo once a week alternately with a neutral shampoo twice a week; and the control group applying the neutral shampoo alone three times a week.</p><p><strong>Results: </strong>Following the intensive phase, the scalp condition improved substantially, as evidenced by a significant decrease in the severity of dandruff, erythema, and pruritus, associated with an improvement of SD dysbiosis. These improvements were more sustained in the test group than in the control group during the maintenance phase. The rediversification of the scalp microbiota involved a significant increase in fungal and bacterial richness along with a decrease in the level of SD-predominant Malassezia fungi and Staphylococcus bacteria and an increase in the level of low-abundant fungi genera belonging to the Ascomycota phylum.</p><p><strong>Conclusions: </strong>The synergistic effects of antimycotic and antiinflammatory agents in the study shampoo likely contributed to rebalancing the fungal and bacterial ecosystem, thus improving scalp symptoms.</p><p><strong>Clinicaltrials: </strong></p><p><strong>Gov identifier: </strong>NCT06578962 (retrospectively registered on 28 August 2024).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2077-2097"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Supplementation with a New Hyaluronic Acid Matrix Ingredient Improves Skin Brightness, Hydration, Smoothness, and Roughness: Results from a Randomized, Double-Blinded, Placebo-Controlled Study.","authors":"Trinidad Montero-Vilchez, Patricia Gálvez-Martín, Raquel Sanabria-de la Torre, Carlos Cuenca-Barrales, Alejandro Molina-Leyva, Daniel Martinez-Puig, Javier Velasco-Alvarez, Salvador Arias-Santiago","doi":"10.1007/s13555-025-01447-6","DOIUrl":"10.1007/s13555-025-01447-6","url":null,"abstract":"<p><strong>Introduction: </strong>The skin aging process is mainly associated with the appearance of fine wrinkles and flaccid, dry, and dull skin. A hyaluronic acid matrix (HAm) ingredient containing HA, sulfated glycosaminoglycans (GAGs), and collagen is proposed to enhance skin health by improving hydration and structural integrity. The objective of this study was to evaluate the impact of oral supplementation with HAm on skin properties.</p><p><strong>Methods: </strong>A 12-week, randomized, double-blind, placebo-controlled trial was designed, including 60 healthy women aged 35-65 with signs of natural skin aging (NCT05813054). Participants were assigned to receive either HAm (Dermial^®; 60 mg daily) or a placebo and were dermatologically assessed after 6 and 12 weeks. Skin properties were determined by the evaluation of stratum corneum hydration (SCH), brightness/glow, wrinkles, dryness, roughness, smoothness, pH, temperature, elasticity, friction, antioxidant capacity, deformability, melanin index, and erythema index. In addition, global satisfaction and adverse reactions were assessed.</p><p><strong>Results: </strong>Assessments were performed on data from 50 participants as a per-protocol analysis. Skin wrinkles and smoothness (6 weeks), and roughness (12 weeks) significantly improved in the HAm group compared with the placebo group. Participants receiving HAm had significantly increased skin SCH and brightness, and decreased scaliness and temperature at 6 and 12 weeks versus the baseline value. A statistically significant reduction in the erythema index and a balanced pH were also observed in the HAm group. Global satisfaction was significantly higher in HAm as compared to placebo. No serious adverse events associated with the tested products were registered during the study.</p><p><strong>Conclusions: </strong>Daily supplementation with HAm effectively improves multiple aspects of skin health and appearance, suggesting its potential as a safe and beneficial antiaging ingredient. These results support the role of HAm in promoting skin brightness/glow and hydration, and reducing the visible effects of aging.</p><p><strong>Trial registration: </strong>ClinicalTrials. gov identifier, NCT05813054.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2099-2116"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis.","authors":"Jonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, Andrew E Pink, Diego Ruiz Dasilva, Shawn G Kwatra, Yousef Binamer, Norito Katoh, Valeria Aoki, Alvaro Moreira, Ayman Grada, Chao Li, Brian Calimlim, Wan-Ju Lee, Christopher G Bunick","doi":"10.1007/s13555-025-01469-0","DOIUrl":"10.1007/s13555-025-01469-0","url":null,"abstract":"<p><strong>Introduction: </strong>Guidance from the Aiming Higher in Eczema/Atopic Dermatitis initiative identified moderate and optimal treatment targets for clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs) and defined minimal disease activity (MDA) as simultaneously meeting optimal targets in ClinRO and PRO. This post hoc analysis investigates the impact of achieving individual optimal targets or MDA on patient health-related quality of life (HRQoL) outcomes in patients with atopic dermatitis.</p><p><strong>Methods: </strong>Patients from phase 3 Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD UP (NCT03568318) were randomized 1:1:1 to receive daily oral upadacitinib at either 15 mg or 30 mg, or placebo for the first 16 weeks. Patients were pooled for this analysis regardless of intervention and stratified into three mutually exclusive response groups meeting optimal, moderate, or neither treatment target for each ClinRO or PRO, and the achievement of MDA at week 16. Impact on the patient's HRQoL was measured across eight outcomes: itch, skin symptoms, quality of life, sleep, daily activities, emotional state, work productivity, and treatment satisfaction.</p><p><strong>Results: </strong>Patients who achieved optimal treatment targets, compared with those achieving moderate or neither treatment target, reported greater improvement in patient HRQoL outcomes (1.1-20.2-fold for optimal versus moderate, 1.3 to > 50-fold for optimal versus neither target, and 1.2-16.3-fold for moderate versus neither target groups). In addition, patients who achieved MDA, versus those achieving optimal ClinRO or PRO alone, were more likely to report improved patient HRQoL outcomes.</p><p><strong>Conclusions: </strong>These results highlight the value of reaching optimal treatment targets and MDA in disease management of atopic dermatitis.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2255-2273"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144495001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Hidradenitis Suppurativa in Special Populations: A Narrative Review.","authors":"Teja Mallela, Luke Passannante, Hiral Patel, Leslie Onyeji, Christopher Sayed","doi":"10.1007/s13555-025-01457-4","DOIUrl":"10.1007/s13555-025-01457-4","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that can be treated with a variety of medical and surgical therapies. However, these therapies carry inherent risks that might be heightened in medically complex patients. This narrative review examines literature for the nuances of standard HS management in immunosuppressed individuals, patients with cancer, and those with gastrointestinal or cardiovascular comorbidities, Down syndrome, and PASH syndrome, a rare condition that is characterized by the presence of pyoderma gangrenosum (PG), acne, and HS. The treatment of HS often requires systemic immunomodulators, and their use necessitates a careful risk-benefit analysis to balance disease control and infection risk in patients who are immunosuppressed. Owing to chronic inflammation, HS is associated with an increased risk of malignancies such as cutaneous squamous cell carcinoma. Vigilant screening and histopathologic evaluation of chronic HS lesions are required for chronic lesions and patients with concurrent cancer. There is a high prevalence of inflammatory bowel disease (IBD) in patients with HS, and this can present unique challenges in management. For example, some biologic therapies commonly used for HS can exacerbate IBD symptoms. Cardiovascular disease is a common comorbidity in HS and demands a multidisciplinary approach to risk assessment and treatment, particularly given the systemic inflammatory burden of HS. Patients with Down syndrome are disproportionately affected by HS and often receive suboptimal treatment, underscoring the need for improved screening and access to therapies. PASH and other related syndromes are rare variants of HS and can be a challenge to manage owing to their unpredictable response to tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) inhibitors. Across these unique populations, surgical intervention continues to be a viable option in refractory cases, even with the risk of impaired wound healing in patients who are immunosuppressed and have cancer. Ultimately, a comprehensive, multidisciplinary approach is essential to optimize HS management in these special populations, integrating surgical and systemic therapies while mitigating associated risks.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1985-1998"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographics, Clinical Characteristics, and Treatment Patterns in Patients with Psoriasis: Insights from the Saudi Arabia Psoriasis Registry (PSORSA).","authors":"Mohammad Ibrahim Fatani, Yousef Binamer, Hajer Y Almudaiheem, Maysa Tariq Eshmawi, Fawaz Hamdi Aljehani, Sultanah Alshammari, Ahmed H Al-Jedai","doi":"10.1007/s13555-025-01436-9","DOIUrl":"10.1007/s13555-025-01436-9","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic immune-mediated inflammatory disease characterized by significant variability in clinical presentation and associated comorbidities. We aimed to describe the baseline demographic and clinical characteristics of patients with psoriasis enrolled in the Psoriasis Registry in Saudi Arabia (PSORSA).</p><p><strong>Methods: </strong>This multicenter cohort study included patients with moderate-to-severe psoriasis from 40 hospitals in Saudi Arabia. Baseline demographics, clinical, and comorbidity data were collected and analyzed. Follow-up assessments were conducted every three months for one year.</p><p><strong>Results: </strong>In total, 482 patients were enrolled. The mean age at diagnosis was 32.2 years, with a median disease duration of 848 days and a mean body mass index of 27.32 kg/m². Male patients comprised 51.8% of the cohort, and 96.5% were Saudi nationals. A positive family history of psoriasis was reported in 17.2% of the participants. A total of 83 patients (17.2%) were documented to have comorbidities. Among these 83 patients, 47 (56.6%) had psoriatic arthritis, 20 (24.1%) had diabetes, and 14 (16.9%) had hypertension. Plaque psoriasis was the most common subtype (94.2%), and the most affected body regions were the upper and lower extremities (88.1% and 85.5%, respectively), followed by the scalp and trunk (75.7% each). The mean PASI score at baseline was 25 ± 13.3, which decreased to 0.32 ± 0.94 by week > 52. Conventional systemic therapies were prescribed to 22.6% of the patients, with methotrexate being the most common agent (18%). Biologic therapies were prescribed to 28.9% of the patients, with adalimumab being the most commonly used (21%). In addition, 12.7% of the cohort received phototherapy. Adverse events occurred in 2.1% of the patients, with cyclosporine contributing to 25% of the reported events.</p><p><strong>Conclusion: </strong>The PSORSA registry provides valuable insights into the demographics, clinical characteristics, and treatment patterns of patients with psoriasis in Saudi Arabia. These findings emphasize the need for real-world data to guide regional psoriasis management strategies.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2031-2045"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urticaria Voices: Real-World Treatment Patterns and Outcomes in Chronic Spontaneous Urticaria.","authors":"Jonathan A Bernstein, Tonya A Winders, Jessica McCarthy, Pallavi Saraswat, Nadine Chapman-Rothe, Tara Raftery, Karsten Weller","doi":"10.1007/s13555-025-01461-8","DOIUrl":"10.1007/s13555-025-01461-8","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic spontaneous urticaria (CSU) is characterized by itchy wheals/hives and/or angioedema lasting longer than 6 weeks. Herein, we describe patients' perspectives from the global Urticaria Voices study reporting treatment patterns, disease burden, treatment satisfaction, and expectations.</p><p><strong>Methods: </strong>This global, cross-sectional online survey was conducted from February to September 2022 in patients with CSU. Eligible patients had a self-reported clinician-provided diagnosis of CSU. Data were analyzed descriptively and reported as percentages (n/N), means (standard deviation [SD]), or 95% confidence intervals.</p><p><strong>Results: </strong>Overall, 582 patients with CSU were included in this analysis (62% women; mean [SD] age: 42.0 [11.9] years). At the time of the survey, patients reported taking 2.9 (2.6) concomitant therapies; most patients (79%) were prescribed H1-antihistamines (H1-AH), of which 42% took first-generation H1-AH and 52% took second-generation H1-AH. Since the initiation of their first prescribed treatment (6.3 [8.2] years), 80% of patients reported H1-AH switching (2.3 times on average), 62% of whom reported up-dosing (2.9 times on average). In addition, 50% reported currently using glucocorticoids (cream: 72.1%; oral: 48.3%; injection: 25.5%) and 33% reported using any biologic (omalizumab: 26%; dupilumab: 16%): montelukast (18%), doxepin (16%), or ciclosporin (16%). Apart from their prescribed treatments, patients reported currently using additional services (dietetic consultations: 21%, psychological support: 19%) and self-care strategies (e.g., using topical creams, avoiding certain clothing and foods) for CSU management. Most patients (65%) reported that their current treatments did not adequately control their CSU symptoms. Overall, 37% of patients reported experiencing stress due to the unpredictable nature of the disease.</p><p><strong>Conclusions: </strong>Despite H1-antihistamine switching and up-dosing, most patients (84%) had inadequately controlled disease. Approximately one-quarter of inadequately controlled patients were escalated to more effective treatments such as biologics. These results suggest a need for additional treatment options for patients with inadequately controlled CSU to provide sustained symptom relief.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2201-2215"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.","authors":"Joseph F Merola, Philip J Mease, April W Armstrong, Vibeke Strand, Thomas Lehman, Stefan Varga, Jiyoon C Choi, Brandon Becker, Yichen Zhong, Matthew J Colombo, Diamant Thaçi, Androniki Bili, Alice B Gottlieb","doi":"10.1007/s13555-025-01428-9","DOIUrl":"10.1007/s13555-025-01428-9","url":null,"abstract":"<p><strong>Introduction: </strong>For patients with psoriasis, psoriatic arthritis can be a painful comorbid condition that is often undiagnosed. It is therefore essential that more research is done to understand which treatments for psoriasis relieve both dermatologic and joint symptoms. This analysis aimed to compare the effects of deucravacitinib vs. placebo or apremilast on joint pain and the impact of musculoskeletal symptoms at weeks 16 and 24 in patients from the POETYK psoriasis (PSO-1; NCT03624127) and POETYK PSO second (PSO-2; NCT03611751) trials who self-reported joint symptoms.</p><p><strong>Methods: </strong>During screening in each trial, patients with psoriasis who reported musculoskeletal complaints completed the self-administered Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire. Scores of ≥ 47 constituted positive screens (PASE positive). Joint pain and the impact of musculoskeletal symptoms were measured using a visual analog scale (VAS), with higher scores denoting worse disease burden.</p><p><strong>Results: </strong>This pooled analysis included 185 patients who screened as PASE-positive in the combined POETYK PSO-1 and PSO-2 trials. Improvement from baseline was greater in patients treated with deucravacitinib vs. placebo at week 16 for joint pain VAS (- 15.2 vs. - 3.2) and joint disease VAS (- 17.4 vs. - 3.8). Improvements from baseline were also greater for patients treated with deucravacitinib vs. apremilast for joint pain VAS (- 22.8 vs. - 8.6) and joint disease VAS (- 19.6 vs. - 8.8) scores at week 24. Greater proportions of deucravacitinib-treated patients also achieved 30%, 50%, and 70% improvements in joint pain and musculoskeletal symptoms and impact VAS scores at weeks 16 and 24 than those who received placebo or apremilast.</p><p><strong>Conclusion: </strong>Findings from this pooled analysis suggest that deucravacitinib may be used in patients with psoriasis to effectively treat both dermatologic and joint symptoms. Graphical abstract available for this article.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2281-2293"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffusion Characteristics of LetibotulinumtoxinA, OnabotulinumtoxinA, and AbobotulinumtoxinA and its Impact on Muscle Relaxation: A Randomized Split-Face Clinical Trial.","authors":"Maxine Bennek, Daniela Rudowitz, Martina Kerscher","doi":"10.1007/s13555-025-01458-3","DOIUrl":"10.1007/s13555-025-01458-3","url":null,"abstract":"<p><strong>Introduction: </strong>Injections with botulinumtoxinA (BoNTA) are the most common nonsurgical aesthetic procedure but carry risks such as unintended muscle diffusion. Understanding formulation behavior is key to optimizing safety and efficacy. This study compares the diffusion characteristics from letibotulinumtoxinA (Leti-BoNTA) to onabotulinumtoxinA (Ona-BoNTA) and abobotulinumtoxinA (Abo-BoNTA) and its impact on muscle relaxation of frontalis muscle.</p><p><strong>Methods: </strong>In a double-blind, randomized trial, 30 healthy adults received Leti-BoNTA on one forehead side and either Ona-BoNTA or Abo-BoNTA on the other. Anhidrosis was measured via Minor's starch test over 6 months, and wrinkle severity was assessed using standardized photography and the Croma Scale.</p><p><strong>Results: </strong>Leti-BoNTA had a significantly smaller maximal anhidrotic area than Ona-BoNTA (-15.1 ± 5.5 cm², p < 0.001) and Abo-BoNTA (-25.2 ± 14.5 cm², p < 0.001). An area under the curve (AUC) analysis confirmed the largest area of anhidrosis for Abo-BONTA over the 6-month period, followed by Ona-BONTA and Leti-BoNTA. Despite its lower diffusion, Leti-BoNTA effectively improved wrinkles, with ≥ 1-point improvement in 92% of subjects by week 2.</p><p><strong>Conclusions: </strong>Leti-BoNTA provides wrinkle reduction with a more limited diffusion, as assessed with the Minor's starch-iodine test. Its precise action in this trial implies to be a viable option when controlled spread is essential.</p><p><strong>Clinical trial registration: </strong>The trial EU CT: 2024-511047-26-01 was registered on 23 March 2024.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2147-2158"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of Skin Diseases in Poland: Analysis of Prevalence and Risk Factors: A Cross-Sectional Study.","authors":"Anna Kubrak, Anna Zimny-Zając, Sebastian Makuch, Łukasz Pawelec, Beata Jankowska-Polańska, Wojciech Tański, Jacek C Szepietowski, Siddarth Agrawal","doi":"10.1007/s13555-025-01464-5","DOIUrl":"10.1007/s13555-025-01464-5","url":null,"abstract":"<p><strong>Introduction: </strong>Although skin diseases are a significant public health concern, epidemiological data for Poland is still lacking. This study aimed to fill this scientific gap by analyzing the prevalence of skin diseases and associated risk factors in the Polish population.</p><p><strong>Methods: </strong>A cross-sectional study was conducted using data from the National Healthy Skin Test (2023), an online questionnaire distributed via the Medonet health platform, involving 27,000 adult Polish internet users. Participants self-reported physician-diagnosed skin conditions. The prevalence of these conditions was assessed, and statistical analysis, including logistic regression, was used to evaluate associations with demographic and socioeconomic factors (age, gender, education level, and urbanization).</p><p><strong>Results: </strong>The most prevalent skin conditions were herpes labialis (40.6%), dandruff (37.6%), hair loss (34.8%), and acne (32.7%), with 89.5% of participants reporting at least one condition. Striking gender differences were observed, with psoriasis (odds ratio [OR] = 2.10, 95% confidence interval [CI]: 1.80-2.30) and tinea pedis (OR = 2.10, 95% CI: 1.90-2.30) in men, while women were more prone to rosacea (OR = 0.6, 95% CI: 0.50-0.70) and hair loss (OR = 0.70, 95% CI: 0.60-0.70). Higher education was unexpectedly associated with an increased risk of multiple conditions, including acne (OR = 1.50, 95% CI: 1.40-1.60) and non-melanoma skin cancer (OR = 1.40, 95% CI: 1.20-1.80), but a decreased risk of psoriasis (OR = 0.90, 95% CI: 0.80-1.00). Urban residents of cities with > 500,000 inhabitants showed a significantly higher prevalence of atopic dermatitis/eczema (OR = 1.20, 95% CI: 1.00-1.30) and non-melanoma skin cancer (OR = 2.00, 95% CI: 1.40-2.90) compared with other areas.</p><p><strong>Conclusions: </strong>This first overview of skin disease epidemiology in Poland reveals significant variations in prevalence based on demographic and socioeconomic factors. These findings have important public health implications, suggesting the need for: (1) gender-specific dermatological education campaigns, (2) age-targeted skin cancer screening programs for those over 65 years, (3) improved access to dermatological care in rural areas, and (4) educational interventions addressing the observed socioeconomic disparities in disease prevalence and detection.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2179-2199"},"PeriodicalIF":3.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}